{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:29:46Z","timestamp":1790623786612,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102452","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:07:24Z","timestamp":1759795644000},"page":"102452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities"],"prefix":"10.1016","volume":"23","author":[{"given":"Chitra Priya","family":"Emperumal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-489X","authenticated-orcid":false,"given":"Bridget P.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0001","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102452_bib0002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102452_bib0004","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102452_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102452_bib0006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.2020.38.6_suppl.124","article-title":"Phase I study of pasotuxizumab (AMG 212\/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Hummel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102452_bib0007","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.869","article-title":"609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE\u00ae) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"31","author":"Tran","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0008","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2025.102452_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","article-title":"Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Falchook","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102452_bib0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0011","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.23765","article-title":"Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer","volume":"79","author":"Petrylak","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102452_bib0012","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","article-title":"1804P APEX-01: first-in-human phase I\/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102452_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far","volume":"98-99","author":"Heynickx","year":"2021","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0014","first-page":"81","article-title":"Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J Med Radiat Sci"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.clgc.2025.102452_bib0017","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0018","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.clgc.2025.102452_bib0019","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ph12010018","article-title":"[(177)Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography","volume":"12","author":"Tonnesmann","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0022","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","article-title":"Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept","volume":"52","author":"Baum","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands","volume":"8","author":"van Kalmthout","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.120.246983","article-title":"The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intraindividual imaging study","volume":"62","author":"Harsini","year":"2021","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0026","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MNM.0000000000001506","article-title":"Reduction of radiation accumulation in salivary glands through oral vitamin C during 68Ga-PSMA-11 total-body dynamic PET\/CT imaging","volume":"43","author":"Yu","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0027","first-page":"548","article-title":"MASCC\/ISOO Clinical Practice Statement: management of salivary gland hypofunction and xerostomia in cancer patients","volume":"32","author":"Hong","year":"2024","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41181-021-00124-1","article-title":"Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?","volume":"6","author":"Felber","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"12","key":"10.1016\/j.clgc.2025.102452_bib0029","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2967\/jnumed.118.215350","article-title":"Monosodium glutamate reduces (68)Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate cancer model","volume":"59","author":"Rousseau","year":"2018","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0030","first-page":"549","article-title":"MASCC\/ISOO Clinical Practice Statement: management of oral complications of targeted therapy","volume":"32","author":"Villa","year":"2024","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/039463201002300113","article-title":"Efficacy of a spray compound containing a pool of collagen precursor synthetic aminoacids (l-proline, l-leucine, l-lysine and glycine) combined with sodium hyaluronate to manage chemo\/radiotherapy-induced oral mucositis: preliminary data of an open trial","volume":"23","author":"Colella","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0032","doi-asserted-by":"crossref","first-page":"S568","DOI":"10.1016\/j.ijrobp.2013.06.1507","article-title":"l-lysine in the treatment of oral mucositis in head-and-neck cancer patients: a pilot study","volume":"87","author":"Wong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.clgc.2025.102452_bib0033","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1938::AID-CNCR18>3.0.CO;2-U","article-title":"A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation","volume":"82","author":"Ripamonti","year":"1998","journal-title":"Cancer"},{"issue":"5B","key":"10.1016\/j.clgc.2025.102452_bib0034","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0035","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/bjc.1995.377","article-title":"Prostate-specific membrane antigen: evidence for the existence of a second related human gene","volume":"72","author":"Leek","year":"1995","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0037","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pros.24254","article-title":"Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue","volume":"82","author":"Yuan","year":"2022","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0038","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/154411130301400305","article-title":"Oral sequelae of head and neck radiotherapy","volume":"14","author":"Vissink","year":"2003","journal-title":"Crit Rev Oral Biol Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0039","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1601-0825.2010.01723.x","article-title":"Stem cells and the repair of radiation-induced salivary gland damage","volume":"17","author":"Coppes","year":"2011","journal-title":"Oral Dis"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0040","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/1097-0142(19910315)67:6<1539::AID-CNCR2820670613>3.0.CO;2-Q","article-title":"Radiation apoptosis of serous acinar cells of salivary and lacrimal glands","volume":"67","author":"Stephens","year":"1991","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102452_bib0041","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF02889885","article-title":"Morphologic and histochemical studies on the differing radiosensitivity of ductular and acinar cells of the rat submandibular gland","volume":"45","author":"Abok","year":"1984","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102452_bib0042","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0043","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","article-title":"The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy","volume":"39","author":"Beauregard","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.clgc.2025.102452_bib0044","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","author":"Kabasakal","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0045","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102452_bib0046","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter?","volume":"59","author":"Taieb","year":"2018","journal-title":"J Nucl Med"},{"issue":"20","key":"10.1016\/j.clgc.2025.102452_bib0047","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.clgc.2025.102452_bib0048","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0022034509343143","article-title":"Sensitivity of salivary glands to radiation: from animal models to therapies","volume":"88","author":"Grundmann","year":"2009","journal-title":"J Dent Res"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0049","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0360-3016(01)01512-7","article-title":"Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer","volume":"50","author":"Eisbruch","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0050","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","article-title":"Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies","volume":"59","author":"Langbein","year":"2018","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0051","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"issue":"17","key":"10.1016\/j.clgc.2025.102452_bib0052","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Hillier","year":"2009","journal-title":"Cancer Res"},{"issue":"10276","key":"10.1016\/j.clgc.2025.102452_bib0053","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.clgc.2025.102452_bib0054","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.clgc.2025.102452_bib0055","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2025.102452_bib0056","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0057","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0003-9969(95)00033-L","article-title":"Measurements of human minor salivary gland secretions from different oral sites","volume":"40","author":"Sivarajasingam","year":"1995","journal-title":"Arch Oral Biol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0058","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0003-9969(73)90156-8","article-title":"The contribution of oral minor mucous gland secretions to the volume of whole saliva in man","volume":"18","author":"Dawes","year":"1973","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.clgc.2025.102452_bib0059","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.archoralbio.2016.05.012","article-title":"Minor salivary glands function is decreased in hyposalivation-related diseases","volume":"69","author":"Wang","year":"2016","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.clgc.2025.102452_bib0060","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.radonc.2020.09.034","article-title":"The tubarial salivary glands: a potential new organ at risk for radiotherapy","volume":"154","author":"Valstar","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0061","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2003.0018","article-title":"Xerostomia: etiology, recognition and treatment","volume":"134","author":"Guggenheimer","year":"2003","journal-title":"J Am Dent Assoc"},{"issue":"8","key":"10.1016\/j.clgc.2025.102452_bib0062","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0063","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clgc.2023.12.008","article-title":"Oral toxicities of PSMA-targeted immunotherapies for the management of prostate cancer","volume":"22","author":"Emperumal","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0064","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms","volume":"59","author":"Salas Fragomeni","year":"2018","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.clgc.2025.102452_bib0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2967\/jnumed.120.257915","article-title":"(68)Ga-PSMA-11 PET\/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma","volume":"62","author":"Hirmas","year":"2021","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0066","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.7150\/jca.63509","article-title":"Expression of prostate-specific membrane antigen (PSMA) in papillary renal cell carcinoma - overview and report on a large multicenter cohort","volume":"13","author":"Zschabitz","year":"2022","journal-title":"J Cancer"},{"issue":"14","key":"10.1016\/j.clgc.2025.102452_bib0067","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.7150\/thno.99035","article-title":"Lutetium-177-PSMA therapy for recurrent\/metastatic salivary gland cancer: a prospective pilot study","volume":"14","author":"van Ruitenbeek","year":"2024","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0068","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.122.264342","article-title":"PSMA-directed imaging and therapy of salivary gland tumors: a single-center retrospective study","volume":"64","author":"Civan","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0069","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13550-021-00866-8","article-title":"First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer","volume":"11","author":"Klein Nulent","year":"2021","journal-title":"EJNMMI Res"},{"issue":"16","key":"10.1016\/j.clgc.2025.102452_bib0070","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1200\/JCO.2023.41.16_suppl.6099","article-title":"177 Lu-PSMA radioligand therapy for patients with recurrent\/metastatic (R\/M) salivary gland cancer (SGC): a phase II pilot study","volume":"41","author":"Van Herpen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102452_bib0071","first-page":"4305","article-title":"Oral examination findings, taste and smell testing during and following head and neck cancer therapy","volume":"28","author":"Epstein","year":"2020","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2025.102452_bib0072","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hed.20162","article-title":"Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis","volume":"27","author":"Duncan","year":"2005","journal-title":"Head Neck"},{"issue":"10","key":"10.1016\/j.clgc.2025.102452_bib0073","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2967\/jnumed.121.262543","article-title":"Safety of PSMA-targeted molecular radioligand therapy with (177)Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC (NCT03042312)","volume":"62","author":"Calais","year":"2021","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102452_bib0074","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc1318","article-title":"The pathobiology of mucositis","volume":"4","author":"Sonis","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cpf.12199","article-title":"Imaging of the major salivary glands","volume":"36","author":"Afzelius","year":"2016","journal-title":"Clin Physiol Funct Imaging"},{"issue":"10","key":"10.1016\/j.clgc.2025.102452_bib0076","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.6004\/jnccn.2014.0142","article-title":"Head and neck cancers, version 2.2014. Clinical practice guidelines in oncology","volume":"12","author":"Pfister","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0077","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijrobp.2006.05.002","article-title":"Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer","volume":"66","author":"Meirovitz","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102452_bib0078","first-page":"45","article-title":"Diagnosis and management of xerostomia and hyposalivation","volume":"11","author":"Villa","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0079","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1742-1241.2009.02132.x","article-title":"Managing the patient presenting with xerostomia: a review","volume":"64","author":"Visvanathan","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0080","first-page":"40","article-title":"Salivary stimulation by chewing gum and lozenges in rheumatic patients with xerostomia","volume":"101","author":"Risheim","year":"1993","journal-title":"Scand J Dent Res"},{"issue":"5","key":"10.1016\/j.clgc.2025.102452_bib0081","first-page":"342","article-title":"Effects of pilocarpine hydrochloride and cevimeline on submandibular\/sublingual salivation in rat xerostomia model produced by X-ray irradiation","volume":"53","author":"Omori","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clgc.2025.102452_bib0082","first-page":"S336","article-title":"Does cooling of the salivary glands reduce uptake of radiolabeled PSMA-ligands?","volume":"42","author":"Gaertner","year":"2015","journal-title":"EAMN"},{"key":"10.1016\/j.clgc.2025.102452_bib0083","first-page":"A2","article-title":"Effekt der K\u00fchlung von Speicheldr\u00fcsen bei der therapie mit PSMA-Radioliganden","volume":"56","author":"Bohn","year":"2017","journal-title":"Nuklearmedizin"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0084","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-021-00803-9","article-title":"Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study","volume":"11","author":"Roy","year":"2021","journal-title":"EJNMMI Res"},{"issue":"7","key":"10.1016\/j.clgc.2025.102452_bib0085","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","article-title":"Deescalated 225Ac-PSMA-617 versus 177Lu\/225Ac-PSMA-617 cocktail therapy: a single-center retrospective analysis of 233 patients","volume":"65","author":"Hendrik Rathke","year":"2024","journal-title":"J Nucl Med"},{"issue":"18","key":"10.1016\/j.clgc.2025.102452_bib0086","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1039\/D3SC06668A","article-title":"DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target","volume":"15","author":"Lucaroni","year":"2024","journal-title":"Chem Sci"},{"issue":"10","key":"10.1016\/j.clgc.2025.102452_bib0087","first-page":"851","article-title":"MASCC\/ISOO clinical practice statement: management of oral complications of immunotherapy","volume":"33","author":"Fregnani","year":"2025","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102452_bib0088","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/lary.22490","article-title":"A double-blind study on clonazepam in patients with burning mouth syndrome","volume":"122","author":"Heckmann","year":"2012","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.clgc.2025.102452_bib0089","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ijc.2910620511","article-title":"Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids","volume":"62","author":"Troyer","year":"1995","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41536-025-00410-5","article-title":"Establishment of salivary tissue-organoid biorepository: characterizing salivary gland stem\/progenitor cells and novel differentiation marker PSMA\/FOLH1","volume":"10","author":"Aalam","year":"2025","journal-title":"NPJ Regen Med"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0091","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2967\/jnumed.122.264946","article-title":"Developing a patient-reported outcome measure for radionuclide therapy for prostate cancer","volume":"64","author":"Gudenkauf","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0092","first-page":"400","article-title":"Oral complications of cancer and cancer therapy: from cancer treatment to survivorship","volume":"62","author":"Epstein","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102452_bib0093","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.radonc.2022.10.038","article-title":"Dose response modelling of secretory cell loss in salivary glands using PSMA PET","volume":"177","author":"Mohan","year":"2022","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102452_bib0094","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.121.262552","article-title":"(177)Lu-PSMA-617 and Idronoxil in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase I\/II trial","volume":"63","author":"Pathmanandavel","year":"2022","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.clgc.2025.102452_bib0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant Prostate cancer: a phase I dose-escalation study of Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10459","key":"10.1016\/j.clgc.2025.102452_bib0096","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0097","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","article-title":"A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [(177)Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer","volume":"51","author":"Zang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0098","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102452_bib0099","article-title":"Initial clinical experience with [(177)Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102452_bib0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0002-8177(87)54012-0","article-title":"Subjective reports of xerostomia and objective measures of salivary gland performance","volume":"115","author":"Fox","year":"1987","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"10.1016\/j.clgc.2025.102452_bib0101","first-page":"12","article-title":"The Xerostomia Inventory: a multi-item approach to measuring dry mouth","volume":"16","author":"Thomson","year":"1999","journal-title":"Community Dent Health"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1067\/moe.2001.111551","article-title":"Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction","volume":"91","author":"Pai","year":"2001","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0103","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.tripleo.2011.03.024","article-title":"Shortening the xerostomia inventory","volume":"112","author":"Thomson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"10","key":"10.1016\/j.clgc.2025.102452_bib0104","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/00220345820610100901","article-title":"A comparison of whole mouth resting and stimulated salivary measurement procedures","volume":"61","author":"Navazesh","year":"1982","journal-title":"J Dent Res"},{"key":"10.1016\/j.clgc.2025.102452_bib0105","series-title":"The Physiological Regulation of Salivary Secretions in Man. International Series of Monographs in Oral Biology","author":"Kerr","year":"1961"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0106","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1469-8986.1977.tb03379.x","article-title":"Salivation: a review and experimental investigation of major techniques","volume":"14","author":"White","year":"1977","journal-title":"Psychophysiology"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0107","doi-asserted-by":"crossref","first-page":"164","DOI":"10.14219\/jada.archive.2005.0137","article-title":"Using the modified Schirmer test to measure mouth dryness: a preliminary study","volume":"136","author":"Chen","year":"2005","journal-title":"J Am Dent Assoc"},{"issue":"3","key":"10.1016\/j.clgc.2025.102452_bib0108","first-page":"116","article-title":"The use of the Schirmer tear test in evaluating mouth dryness","volume":"60","author":"Davis","year":"1986","journal-title":"Dent Hyg (Chic)"},{"issue":"6","key":"10.1016\/j.clgc.2025.102452_bib0109","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1037\/h0073282","article-title":"Reflex secretion of the human parotid gland","volume":"1","author":"Lashley","year":"1916","journal-title":"J Exp Psy"},{"key":"10.1016\/j.clgc.2025.102452_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1152\/ajplegacy.1910.26.1.169","article-title":"The relation of ptyalin concentration to the diet and to the rate of secretion of saliva","volume":"26","author":"Carlson","year":"1910","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0111","first-page":"93","article-title":"A parotid fluid collection device with improved stability characteristics","volume":"4","author":"Shannon","year":"1967","journal-title":"J Oral Ther Pharmacol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102452_bib0112","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1177\/00220345970760111001","article-title":"A novel system of human submandibular\/sublingual saliva collection","volume":"76","author":"Wolff","year":"1997","journal-title":"J Dent Res"},{"issue":"5","key":"10.1016\/j.clgc.2025.102452_bib0113","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1177\/00220345900690050501","article-title":"A method for measuring the flow of saliva from the minor salivary glands","volume":"69","author":"Shern","year":"1990","journal-title":"J Dent Res"},{"issue":"2","key":"10.1016\/j.clgc.2025.102452_bib0114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.11613\/BM.2015.018","article-title":"Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review","volume":"25","author":"Nunes","year":"2015","journal-title":"Biochem Med (Zagreb)"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:08:21Z","timestamp":1770671301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001521"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102452","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102452"}}